Explore Hikma Pharmaceuticals's Fair Values from the Community and select yours

From what we can see, insiders were net buyers in Hikma Pharmaceuticals PLC's (LON:HIK ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The Last 12 Months Of Insider Transactions At Hikma Pharmaceuticals

In fact, the recent purchase by Mazen Samih Darwazah was the biggest purchase of Hikma Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, even at a higher price than the current share price (being UK£17.40). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Mazen Samih Darwazah was the only individual insider to buy during the last year.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for Hikma Pharmaceuticals LSE:HIK Insider Trading Volume August 10th 2025

Hikma Pharmaceuticals is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations,  this freelist of growing companies with recent insider purchasing, could be just the ticket.

Insiders At Hikma Pharmaceuticals Have Bought Stock Recently

Over the last three months, we've seen significantly more insider buying, than insider selling, at Hikma Pharmaceuticals. In total, Executive Vice Chairman & President of MENA Mazen Samih Darwazah bought UK£3.5m worth of shares in that time. But Executive Vice President of Corporate Development and M&A Bassam Wael Kanaan sold shares worth UK£842k. We think insiders may be optimistic about the future, since insiders have been net buyers of shares.

Insider Ownership Of Hikma Pharmaceuticals

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Hikma Pharmaceuticals insiders own 2.1% of the company, currently worth about UK£81m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

Story Continues

So What Does This Data Suggest About Hikma Pharmaceuticals Insiders?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. Insiders likely see value in Hikma Pharmaceuticals shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Hikma Pharmaceuticals. Case in point: We've spotted 1 warning sign for Hikma Pharmaceuticals you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this freelist of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments